Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial
Publication
, Journal Article
Wysham, WZ; Schaffer, EM; Coles, TM; Roque, DR; Wheeler, SB; Kim, KH
Published in: Gynecologic Oncology
June 2016
Duke Scholars
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
June 2016
Volume
141
Start / End Page
36 / 36
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Wysham, W. Z., Schaffer, E. M., Coles, T. M., Roque, D. R., Wheeler, S. B., & Kim, K. H. (2016). Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial. Gynecologic Oncology, 141, 36–36. https://doi.org/10.1016/j.ygyno.2016.04.116
Wysham, W. Z., E. M. Schaffer, T. M. Coles, D. R. Roque, S. B. Wheeler, and K. H. Kim. “Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial.” Gynecologic Oncology 141 (June 2016): 36–36. https://doi.org/10.1016/j.ygyno.2016.04.116.
Wysham WZ, Schaffer EM, Coles TM, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial. Gynecologic Oncology. 2016 Jun;141:36–36.
Wysham, W. Z., et al. “Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial.” Gynecologic Oncology, vol. 141, Elsevier BV, June 2016, pp. 36–36. Crossref, doi:10.1016/j.ygyno.2016.04.116.
Wysham WZ, Schaffer EM, Coles TM, Roque DR, Wheeler SB, Kim KH. Adding bevacizumab to single-agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost-effectiveness analysis of the AURELIA trial. Gynecologic Oncology. Elsevier BV; 2016 Jun;141:36–36.
Published In
Gynecologic Oncology
DOI
ISSN
0090-8258
Publication Date
June 2016
Volume
141
Start / End Page
36 / 36
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3215 Reproductive medicine
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1114 Paediatrics and Reproductive Medicine
- 1112 Oncology and Carcinogenesis